137 related articles for article (PubMed ID: 36628976)
1. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction.
Shi CR; Shaughnessy M; Sehgal K; Clark JR; Reynolds KL; Toyohara J; Chen ST
Int J Dermatol; 2023 Oct; 62(10):1292-1294. PubMed ID: 36628976
[No Abstract] [Full Text] [Related]
2. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer.
Riano I; Cristancho C; Treadwell T
J Investig Med High Impact Case Rep; 2020; 8():2324709620914796. PubMed ID: 32207346
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications.
Ryu S; Jun I; Kim TI; Seo KY; Kim EK
Ocul Immunol Inflamm; 2022 Aug; 30(6):1533-1535. PubMed ID: 33826467
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.
Saw S; Lee HY; Ng QS
Eur J Cancer; 2017 Aug; 81():237-239. PubMed ID: 28438440
[No Abstract] [Full Text] [Related]
5. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
[TBL] [Abstract][Full Text] [Related]
7. Progressive rash, oral lesions, and history of antibiotic use in a 17-year-old boy: Stevens-Johnson syndrome: a case report.
Barrick C; Macatuno E
Clin Pediatr (Phila); 2014 Oct; 53(11):1101-5. PubMed ID: 24807982
[No Abstract] [Full Text] [Related]
8. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction.
Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L
Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146
[No Abstract] [Full Text] [Related]
9. Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.
Haratake N; Tagawa T; Hirai F; Toyokawa G; Miyazaki R; Maehara Y
J Thorac Oncol; 2018 Nov; 13(11):1798-1799. PubMed ID: 29885481
[No Abstract] [Full Text] [Related]
10. Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
Eldani C; Darrigade AS; Beylot-Barry M; Jullie ML; Ducharme O; Milpied B; Pham-Ledard A
Eur J Dermatol; 2022 Nov; 32(6):805-807. PubMed ID: 36856394
[No Abstract] [Full Text] [Related]
11. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
Robinson S; Saleh J; Curry J; Mudaliar K
Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor.
Horii M; Kobayashi T; Maeda S; Takehara K; Matsushita T
J Dermatol; 2019 Nov; 46(11):e434-e436. PubMed ID: 31342541
[No Abstract] [Full Text] [Related]
13. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.
Lomax AJ; McQuillan PIA; Hall A; McArthur GA
Intern Med J; 2019 Aug; 49(8):1051-1053. PubMed ID: 31387152
[No Abstract] [Full Text] [Related]
14. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
15. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
[TBL] [Abstract][Full Text] [Related]
17. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.
Batinac T; Hlača N; Simetić L; Valković F; Peternel S; Prpić-Massari L
Acta Derm Venereol; 2022 Feb; 102():adv00650. PubMed ID: 35146529
[No Abstract] [Full Text] [Related]
18. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease.
Mounach A; Rezqi A; Nouijai A; Ghozlani I; Achemlal L; Maghraoui AE; Bezza A
Rheumatol Int; 2013 May; 33(5):1351-3. PubMed ID: 22187054
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab induced toxic epidermal necrolysis.
Kumar R; Bhandari S
Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
[No Abstract] [Full Text] [Related]
20. Stevens-Johnson Syndrome associated with methotrexate treatment for acute lymphoblastic leukemia: a case report.
Akıncı B; Siviş ZÖ; Şahin A; Karapınar DY; Balkan C; Kavaklı K; Aydınok Y
Arch Argent Pediatr; 2018 Jun; 116(3):e459-e462. PubMed ID: 29756724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
